EntryPoint Capital’s Halozyme HALO Stock Holding History

EntryPoint Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,148	Closed	-$304K	–	744
2025 Q3	$304K	Buy	+4,148	New	+$276K	0.12%	365
2025 Q2	–	Sell	-7,906	Closed	-$504K	–	694
2025 Q1	$504K	Buy	7,906 +3,094	+64%	+$180K	0.23%	103
2024 Q4	$230K	Buy	+4,812	New	+$247K	0.1%	523

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EntryPoint Capital's HALO Position: Q4 2025 in Review

EntryPoint Capital sold out of Halozyme (HALO) in Q4 2025, closing a stake of 4,148 shares — an estimated $304K sold.

EntryPoint Capital first reported a position in HALO in Q4 2024 and held it in 3 quarters. The position peaked at $504K in Q1 2025. 619 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

EntryPoint Capital reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 4,148 Halozyme shares in Q4 2025, an estimated $304K.
EntryPoint Capital first reported a position in Halozyme in Q4 2024 and held it in 3 quarters.
EntryPoint Capital's Halozyme position peaked at $504K in Q1 2025.
619 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.